Browse All

Current Filters

CLEAR FILTER x

TITLE

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study

Author:Bermel, Robert   Hartung, Hans-Peter   Brochet, Bruno   Benedict, Ralph   Berger, Thomas   Carroll, William   Vollmer, Timothy   Holmoy, Trygve   Karabudak, Rana   Killestein, Joep   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Wuerfel, Jens   Kuenzel, Thomas   Kadner, Karen   Kulyk, Inessa   Freedman, Mark   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.004  

Author Institution:Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Deptartment of Neurology, Heinrich-Heine-University Düsseldorf, Germany, Dusseldorf, Germany  Université de Bordeaux, Neurocentre Magendie INSERM, Bordeaux, France, Bordeaux, France  Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY  Dept. of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA, Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute Ottawa, ON, Canada., Ottawa, ON, Canada  

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis

Author:Arnold, Douglas L.   Freeman, Leorah   Hartung, Hans-Peter   Montalbán, Xavier   Cohen, Jeffrey A.   Bar-Or, Amit   Steinman, Lawrence   DeLuca, John   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Pachai, Chahin   Cree, Bruce A. C.   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.010  

Author Institution:NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montréal, QC, Canada  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, Newark, NJ  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA